Cryptotanshinone inhibits human glioma cell proliferation by suppressing STAT3 signaling

Malignant gliomas (MGs) are among the most aggressive types of cancers in the human brain. Frequent tumor recurrence caused by a lack of effective therapeutic approaches results in a poor prognosis. Signal transducer and activator of transcription 3 (STAT3), an oncogenic protein, is constitutively activated in MGs and predicts a poor clinical outcome. STAT3 therefore is considered to be a promising target for the treatment of MGs. Cryptotanshinone (CTS), the main bioactive compound from the root of Salvia miltiorrhiza Bunge, has been reported to have various pharmacological effects. However, little is known about its function in MG cells. In this study, we evaluated the effect of CTS on the proliferation of human glioma cell lines (T98G and U87). Our results revealed that CTS significantly suppresses glioma cell proliferation. The phosphorylation of STAT3 Tyr705, but not Ser727, was inhibited by CTS, and STAT3 nuclear translocation was attenuated. Overexpression of constitutively active mutant STAT3C reversed the inhibitory effect of CTS, while knockdown STAT3 showed a similar inhibitory effect as CTS treatment. Following the downregulation of STAT3-regulated proteins cyclinD1 and survivin, cell cycle progression significantly arrested in G1/G0 phase. These results indicate that CTS may be a potential antiproliferation agent for the treatment of MGs and that its mechanism may be related to the inhibition of STAT3 signaling.

[1]  V. Seifert,et al.  Dietary Curcumin Attenuates Glioma Growth in a Syngeneic Mouse Model by Inhibition of the JAK1,2/STAT3 Signaling Pathway , 2010, Clinical Cancer Research.

[2]  Jeanne Kowalski,et al.  The high-mobility group A1a/signal transducer and activator of transcription-3 axis: an achilles heel for hematopoietic malignancies? , 2008, Cancer research.

[3]  G. Blackburn,et al.  Bioactive tanshinones in Salvia miltiorrhiza inhibit the growth of prostate cancer cells in vitro and in mice , 2011, International journal of cancer.

[4]  Wenhua Zheng,et al.  Cryptotanshinone, a compound from Salvia miltiorrhiza modulates amyloid precursor protein metabolism and attenuates β-amyloid deposition through upregulating α-secretase in vivo and in vitro , 2009, Neuroscience Letters.

[5]  W. Meng,et al.  Growth-inhibitory and apoptosis-inducing effects of tanshinones on hematological malignancy cells and their structure–activity relationship , 2012, Anti-cancer drugs.

[6]  H. Lo.  Targeting Ras-RAF-ERK and its interactive pathways as a novel therapy for malignant gliomas. , 2010, Current cancer drug targets.

[7]  D. Stacey.  Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. , 2003, Current opinion in cell biology.

[8]  Xiuzhen Han,et al.  Cryptotanshinone Inhibits Cancer Cell Proliferation by Suppressing Mammalian Target of Rapamycin–Mediated Cyclin D1 Expression and Rb Phosphorylation , 2010, Cancer Prevention Research.

[9]  J. Margolick,et al.  Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance , 2007, Proceedings of the National Academy of Sciences.

[10]  NewtonHB.  Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors , 2004 .

[11]  J. Uhm,et al.  The transcriptional network for mesenchymal transformation of brain tumours , 2010 .

[12]  Z. Zuo,et al.  Pharmacokinetic characterization of hydroxylpropyl-beta-cyclodextrin-included complex of cryptotanshinone, an investigational cardiovascular drug purified from Danshen (Salvia miltiorrhiza). , 2008, Xenobiotica; the fate of foreign compounds in biological systems.

[13]  I. Kang,et al.  Cryptotanshinone induces ER stress-mediated apoptosis in HepG2 and MCF7 cells , 2011, Apoptosis.

[14]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.

[15]  L. Gu,et al.  Pharmacokinetic characterization of hydroxylpropyl-β-cyclodextrin-included complex of cryptotanshinone, an investigational cardiovascular drug purified from Danshen (Salvia miltiorrhiza) , 2008 .

[16]  Y. M. Kim,et al.  Cryptotanshinone, a lipophilic compound of Salvia miltiorrriza root, inhibits TNF-alpha-induced expression of adhesion molecules in HUVEC and attenuates rat myocardial ischemia/reperfusion injury in vivo. , 2009, European journal of pharmacology.

[17]  K. Shiraki,et al.  Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16INK4a and Cdk2/Cyclin E complex activation , 2000, Oncogene.

[18]  Timothy C Ryken,et al.  Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. , 2006, Neurosurgical focus.

[19]  K. Aldape,et al.  Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. , 2012, Neuro-oncology.

[20]  Suyun Huang.  Regulation of Metastases by Signal Transducer and Activator of Transcription 3 Signaling Pathway: Clinical Implications , 2007, Clinical Cancer Research.

[21]  P. Kleihues,et al.  Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. , 2005, Journal of neuropathology and experimental neurology.

[22]  H. Newton.  Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis , 2004, Expert review of anticancer therapy.

[23]  M. Don,et al.  Cryptotanshinone inhibits chemotactic migration in macrophages through negative regulation of the PI3K signaling pathway , 2007, British journal of pharmacology.

[24]  Y. Kajimoto,et al.  Transcriptional expression of survivin and its splice variants in brain tumors in humans. , 2003, Journal of neurosurgery.

[25]  S. Rane,et al.  Janus kinases: components of multiple signaling pathways , 2000, Oncogene.

[26]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[27]  A. Heimberger.  The therapeutic potential of inhibitors of the signal transducer and activator of transcription 3 for central nervous system malignancies , 2011, Surgical neurology international.

[28]  S. Weiss,et al.  On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells. , 2013, Neuro-oncology.

[29]  C. Kruchko,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. , 2012, Neuro-oncology.

[30]  D. Schiffer,et al.  Cyclin D1 expression in gliomas , 1998, Acta Neuropathologica.

[31]  D. Han,et al.  Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. , 2009, Cancer research.

[32]  A. Heimberger,et al.  Small molecular inhibitors of p-STAT3: novel agents for treatment of primary and metastatic CNS cancers. , 2008, Recent patents on CNS drug discovery.

[33]  M. N. Somchit,et al.  Cryptotanshinone attenuates in vitro oxLDL-induced pre-lesional atherosclerotic events. , 2011, Planta medica.

[34]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[35]  Peiqing Liu,et al.  Cryptotanshinone Suppressed Inflammatory Cytokines Secretion in RAW264.7 Macrophages through Inhibition of the NF-κB and MAPK Signaling Pathways , 2011, Inflammation.